THE PRESENT INVENTION RELATES TO PHARMACEUTICAL FORMULATIONS, IN PARTICULAR NOVEL PHARMACEUTICAL FORMULATIONS IN WHICH THE ACTIVE INGREDIENT COMPRISES HUMAN ANTIBODIES TO HUMAN INTERLEUKIN I BETA (IL-1β), IN PARTICULAR ACZ885 ANTIBODY, PHARMACEUTICAL FORMULATIONS WHICH ARE STABLE AND AGGREGATE-FREE UPON STORAGE AND DELIVERY.